Meningococcal Meningitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Meningococcal meningitis, caused by Neisseria meningitidis, is a form of meningitis characterized by inflammation of the membranes surrounding the brain or spinal cord, known as meninges. This inflammation may manifest suddenly (acute) or gradually (subacute). Common symptoms include fever, headache, stiff neck, and muscle soreness, with additional symptoms like nausea, vomiting, and skin rashes occurring in approximately half of affected patients. The incubation period typically lasts 3-4 days, ranging from 1 to 10 days, during which the infection spreads rapidly, surpassing other forms of acute bacterial meningitis in speed. Meningococcal meningitis often follows respiratory illness or a sore throat in adults and children. The disease involves the central nervous system and can progress rapidly, leading to severe complications such as circulatory collapse and diffuse intravascular coagulation (DIC). Acute cases are marked by fever, headache, stiff neck, nausea, vomiting, and altered mental states, including confusion or coma. The illness can rapidly worsen, with adults potentially becoming critically ill within hours, and even shorter durations of infection are observed in children. In October 2023, the FDA approved Penbraya, a vaccine designed to safeguard adolescents against the five most prevalent serogroups responsible for meningococcal disease. Penbraya represents a breakthrough as the first vaccine offering broad protection against these bacteria, which can trigger meningitis and blood poisoning.
- In the United States, the incidence of meningococcal meningitis ranges from 1 to 1.45 cases per 100,000 individuals, with males slightly more affected, constituting 55% of all cases. Infants, children, and young adults are at heightened risk for contracting this illness.
Thelansis’s “Meningococcal Meningitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Meningococcal Meningitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Meningococcal Meningitis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Meningococcal Meningitis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment